Cat. No. | Product name | CAS No. |
DCC1896 |
Ebmi-13b
Highly potent and selective activator of isozymes CA-VA and CA-VII |
21202-53-9 |
DCC1897 |
Ebopiprant
Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist |
2005486-31-5 |
DCC1898 |
Ebov-in-c31
Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties |
752216-12-9 |
DCC1899 |
Ebselen Oxide
Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis |
104473-83-8 |
DCC1900 |
Ebv Activator C60
Novel EBV activator, well-performing EBV lytic cycle inducer |
1031658-01-1 |
DCC1901 |
Ecdsbb-in-12
Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme |
112749-52-7 |
DCC1902 |
Ecdsbb-in-9
Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria |
41933-33-9 |
DCC1903 |
Echinoside A
Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle |
75410-53-6 |
DCC1904 |
Ecraprost
Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders |
136892-64-3 |
DCC1905 |
Edoxaban Isomer
An impurity of Edoxaban, a novel inhibitor of factor Xa |
1255529-24-8 |
DCC1906 |
Eef2k-in-21i
Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways |
|
DCC1907 |
Efatutazone
Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity |
223132-37-4 |
DCC1908 |
Efonidipine
Calcium channel blocker, blocking both T-type and L-type calcium channels |
111011-63-3 |
DCC1909 |
Efrapeptin F
Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo |
131353-66-7 |
DCC1910 |
Efrotomycin
Antibiotic, inhibiting bacterial protein synthesis |
56592-32-6 |
DCC1911 |
Egfr T790m Inhibitor 6a
Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer |
|
DCC1912 |
Egfr-in-451
Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis |
220576-72-7 |
DCC1913 |
Egfr-in-542
Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications |
1639040-81-5 |
DCC1914 |
Egfr-in-557
Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis |
1639040-91-7 |
DCC1915 |
Egis-11150
Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors. |
494861-87-9 |
DCC1916 |
Egis-8332
Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination |
220725-87-1 |
DCC1917 |
Egonol
Antibacterial agent |
530-22-3 |